We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+41.47%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.2B
AUM Growth
+$1.6B
Cap. Flow
+$825M
Cap. Flow %
19.63%
Top 10 Hldgs %
44.15%
Holding
117
New
24
Increased
10
Reduced
49
Closed
12

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$207M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$150M
3
BCAB icon
BioAtla
BCAB
+$76.6M
4
CCCC icon
C4 Therapeutics
CCCC
+$72.2M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$48.8M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$61.3M
2
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$50.2M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$35.5M
4
TWST icon
Twist Bioscience
TWST
+$30.5M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 78.9%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMER icon
26
Omeros
OMER
$959M
$57.1M 1.36%
4,000,000
-1,000,000
-20% -$12.2M
ZYME icon
27
Zymeworks
ZYME
$1.67B
$56.7M 1.35%
1,200,000
+50,000
+4% +$2.32M
XLRN
28
DELISTED
Acceleron Pharma
XLRN
$54.4M 1.29%
425,000
-75,000
-15% -$8.79M
IGMS
29
DELISTED
IGM Biosciences
IGMS
$53M 1.26%
600,000
+375,000
+167% +$26.4M
VIE
30
DELISTED
Viela Bio, Inc. Common Stock
VIE
$51.4M 1.22%
1,429,200
-155,800
-10% -$5.46M
MYOV
31
DELISTED
Myovant Sciences Ltd.
MYOV
$47M 1.12%
1,700,000
-434,966
-20% -$8.47M
BHVN
32
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$36.4M 0.87%
425,000
-75,000
-15% -$6.36M
AXNX
33
DELISTED
Axonics, Inc. Common Stock
AXNX
$34.6M 0.82%
693,000
– –
ALGS icon
34
Aligos Therapeutics
ALGS
$34.9M
$34.5M 0.82%
+50,687
New +$24.7M
TWST icon
35
Twist Bioscience
TWST
$7.25B
$31.8M 0.76%
225,000
-275,000
-55% -$30.5M
SRNE
36
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$30.7M 0.73%
4,500,000
-1,500,000
-25% -$12M
CRSP icon
37
CRISPR Therapeutics
CRSP
$5.17B
$30.6M 0.73%
200,000
-100,000
-33% -$11.8M
MASS icon
38
908 Devices
MASS
$364M
$29.5M 0.7%
+545,322
New +$31.9M
DMRA
39
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$26.5M 0.63%
+86,029
New +$32M
ZLAB icon
40
Zai Lab
ZLAB
$2.62B
$25.6M 0.61%
189,092
– –
BPMC
41
DELISTED
Blueprint Medicines
BPMC
$25.2M 0.6%
225,000
-50,000
-18% -$5.27M
CABA icon
42
Cabaletta Bio
CABA
$455M
$23.8M 0.57%
1,904,424
-162,878
-8% -$2.11M
SPRY icon
43
ARS Pharmaceuticals
SPRY
$612M
$23.2M 0.55%
+500,000
New +$16.7M
BNTX icon
44
BioNTech
BNTX
$23.5B
$22.4M 0.53%
275,000
-50,000
-15% -$4.91M
AGEN
45
Agenus
AGEN
$290M
$22.3M 0.53%
356,650
-76,425
-18% -$5.67M
ELDN icon
46
Eledon Pharmaceuticals
ELDN
$285M
$21.4M 0.51%
+1,415,500
New +$27M
KURA icon
47
Kura Oncology
KURA
$850M
$21.2M 0.51%
650,000
+150,000
+30% +$5.27M
FHTX icon
48
Foghorn Therapeutics
FHTX
$360M
$20.3M 0.48%
+1,000,000
New +$19.2M
AKRO
49
DELISTED
Akero Therapeutics
AKRO
$19.2M 0.46%
742,549
-117,001
-14% -$3.25M
INSP icon
50
Inspire Medical Systems
INSP
$1.74B
$18.8M 0.45%
100,000
-20,000
-17% -$3.27M
1
2
3 4 5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Cormorant Asset Management held 117 positions worth $4.2B, up 62% from $2.6B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management deployed $825M of net new capital in Q4 2020, opening 24 new positions and adding to 10 existing holdings. Its largest new stake was Atea Pharmaceuticals: 6,411,355 shares worth $260M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $30.5M trimmed.

  • Cormorant Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 6,411,355 shares worth $260M.
  • Cormorant Asset Management added most to Forma Therapeutics Holdings, Inc. Common Stock in Q4 2020, an estimated $47M increase.
  • Cormorant Asset Management's biggest Q4 2020 reduction was Twist Bioscience, cutting an estimated $30.5M.
  • Cormorant Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $61.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $4.2B portfolio in Q4 2020.
  • Cormorant Asset Management opened 24 new positions and closed 12 in Q4 2020.
  • Cormorant Asset Management's portfolio value rose 62% quarter-over-quarter to $4.2B.

Based on Cormorant Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.